Document:

CMC Heartland Partners                 Exhibit 10.32
                      330 North Jefferson Court, Suite 305
                             Chicago, Illinois 60661

                                October 17, 2000
Mr. Edwin Jacobson
161 East Chicago Avenue
Apartment 43H
Chicago, Illinois 60611

            Re:   Second Amendment to Employment Agreement

Dear Mr. Jacobson:

            This letter  constitutes  the Second  Amendment  to your  Employment
Agreement  with CMC Heartland  Partners  dated  December 20, 1999 and heretofore
amended by the First Amendment(the Employment Agreement as heretofore amended is
referred to herein as the "Employment Agreement").

            The following  Section  3(b)(iii)  hereby is added to the Employment
Agreement immediately following Section 3(b)(ii):

                  "(iii)Notwithstanding  any  provision  herein to the contrary,
                  whenever  the  Company  is to make an  incentive  compensation
                  payment to you under Section 3(b),  the Company shall have the
                  right to  deduct  forty  percent  (40%) of that  payment  (the
                  "Off-Set Amount") and apply the Off-Set Amount to indebtedness
                  from you to the Company."

            Except as amended by this letter,  the Employment  Agreement remains
in full force and effect in accordance with its terms.

            If the foregoing is satisfactory,  please indicate your agreement by
signing and returning to the Company the enclosed copy of this letter  whereupon
this will constitute the Second Amendment of the Employment Agreement.

ACCEPTED AND AGREED TO:             CMC HEARTLAND PARTNERS

                                    By:   Heartland Technology, Inc.
                                          as General Managing Partner

                                    By:
------------------------------------    ---------------------------------------
Edwin Jacobson
                                    Name: Richard P. Brandstatter

                                    Title:Vice President-Finance
                                          Secretary and Treasurer

                                       -1-

L:\Share\HPLP\EJ empl agrmnt amend 2000.wpdExhibit 10.33

                              AMENDMENT AGREEMENT
                                      TO
                             MANAGEMENT AGREEMENT

            This  Amendment  Agreement,  dated  October 19,  2000,  by and among
Heartland  Partners,  L.P., a Delaware limited  partnership  ("Heartland"),  CMC
Heartland   Partners,   a   Delaware   general   partnership   (the   "Operating
Partnership"),  and  Heartland  Technology,  Inc.,  a Delaware  corporation  (as
successor  in interest to Chicago  Milwaukee  Corporation  under the  Management
Agreement hereinafter defined) (the "Manager").

            WHEREAS,  Heartland,  the Operating  Partnership and the Manager are
parties to a  Management  Agreement  dated as of June 27, 1990 (the  "Management
Agreement")  and desire to extend  the term  thereof,  effective  as of June 26,
2000.

            NOW THEREFORE, the parties hereto agree as follows:

            1.    Section 7(a) of the Management Agreement hereby is amended,
effective as of June 26, 2000, to read as follows:

                  (a) The term of this  Agreement  shall continue until June 27,
                      2005.

            2.    The Management Agreement, as amended by Section 1 hereof,
shall continue in full force and effect.

            IN WITNESS  WHEREOF,  the  parties  hereto  have duly  executed  and
delivered this Amendment Agreement.

                                          HEARTLAND PARTNERS, L.P.
                                          By: Heartland Technology, Inc.
                                                as General Managing Partner

                                          By:
                                              ----------------------------------
                                          Name:
                                                --------------------------------
                                          Title:
                                                 -------------------------------

                                     -1-

<PAGE>

                                          CMC HEARTLAND PARTNERS
                                          By: Heartland Technology, Inc.
                                                as General Managing Partner

                                          By:
                                              ----------------------------------
                                          Name:
                                                --------------------------------
                                          Title:
                                                 -------------------------------

                                          HEARTLAND TECHNOLOGY, INC.

                                          By:
                                              ----------------------------------
                                          Name:
                                                --------------------------------
                                          Title:
                                                 -------------------------------

L:\Share\HPLP\amendmnt to mgt agreement 2000.wpd

                                     -2-<PAGE> 1
                                   CONFIDENTIAL MATERIAL OMITTED AND
                                   FILED SEPARATELY WITH THE SECURITIES AND
                                   EXCHANGE COMMISSION (*Denotes Omission)
                                            EXHIBIT 10.1 (REDACTED)

                                    AGREEMENT

THIS AGREEMENT is made effective as of the 1st day of January, 1999, between
IDEXX Europe B.V., a corporation organized under the law of The Netherlands
whose principal place of business is at Koolhovenlaan 20, 1119 NE - Schiphol-
Rijk, The Netherlands ("IDEXX") and Ortho-Clinical Diagnostics, Inc., a New York
corporation with offices at 100 Indigo Creek Drive, Rochester, New York, U.S.A.
("OCD").

WHEREAS, OCD and IDEXX desire to enter into supply arrangements with respect to
VITROS slides for use on the VETTEST analyzer;

NOW THEREFORE, the parties hereby agree as follows:

1.      DEFINITIONS

In this Agreement the following expressions shall have the meaning set opposite
them.

"Agreements"                  This Agreement and the US Agreement.

"Applicable Percentage"       The percentage obtained by dividing (i) the unit
                              volume of slide sales for a particular chemistry
                              in a given period, BY (ii) the unit volume of
                              slide sales for all chemistries listed on SCHEDULE
                              5 for such period  (as such SCHEDULE 5 may from
                              time to time be revised).  Applicable Percentages
                              of unit volume sales shall be determined based on
                              sales in the most recently completed fiscal
                              quarter, and the sum of the Applicable Percentages
                              shall always be 100%.

"Commencement Date"           January 1, 1999.

"Corresponding Slide"         Any VITROS slide which provides the same blood
                              chemistry measurement as a particular VETTEST
                              slide (e.g., a DT60 Glucose slide is a
                              Corresponding Slide for a VETTEST Glucose slide).

"DT60"                        The DT60 analyzer developed by OCD for human
                              biomedical purposes and using the VITROS slides.

"Effective Rebate Rate"       For any year, the weighted average percentage
                              reduction in the purchase price of any slides
                              purchased in such year that IDEXX is entitled to
                              receive pursuant to Section 7.03 hereunder.  The
<PAGE> 2
                              calculation of the Effective Rebate Rate is
                              illustrated in SCHEDULE 6.

"IDEXX US"                    IDEXX Laboratories, Inc., a Delaware corporation.

"PANELS/PROFILES"             Packages of VETTEST slides consisting of two or
                              more sets of slides of specified chemistries.  The
                              initial PANEL and the initial PROFILES shall
                              consist of the slides set forth on SCHEDULE 3
                              attached hereto, with any changes or additional
                              PANELS/PROFILES to be mutually agreed upon by the
                              parties as specified in SCHEDULE 3.

"Prime Rate"                  For any day in any calendar month, the prime rate
                              of interest as published in the WALL STREET
                              JOURNAL on the last business day of the
                              immediately preceding month.

"Proportionate Share"         The percentage obtained by dividing (i) the number
                              of VETTEST slides purchased by IDEXX in a given
                              period, BY (ii) the total number of VETTEST slides
                              purchased by IDEXX and its affiliates during such
                              period.

"Term"                        The period from January 1, 1999 until December 31,
                              2010.

"US Agreement"                The Agreement effective as of January 1, 1999
                              between OCD and IDEXX US, as amended and from time
                              to time in effect.

"VETTEST analyzer"            The VETTEST VT 8008 analyzer developed by or on
                              behalf of VETTEST S.A., predecessor of IDEXX US,
                              for veterinary purposes and using VITROS slides;
                              including (i) any updates or modifications to such
                              analyzer, or (ii) other chemistry testing
                              instrument which, in the case of clause (i) and
                              (ii), is designed by IDEXX US to be the bridging
                              instrument to a next-generation veterinary
                              chemistry analyzer ***************
                              *******************************.

******************            ************************************
                              **********************
<PAGE> 3
"VETTEST slides"              VITROS or other OCD chemistry slides specially bar
                              coded, labeled, and/or packaged for the VETTEST
                              analyzer in accordance with the terms of this
                              Agreement and supplied by OCD in accordance with
                              the terms and conditions of this Agreement.

"VETTEST tips"                Metering tips manufactured by OCD for use with
                              VITROS 700 Analyzer specially packaged and
                              supplied to IDEXX in accordance with the terms of
                              this Agreement.

"VITROS slides"               The slides developed by OCD for use in any VITROS
                              analyzer.

"Weighted Average List Price" The product obtained by multiplying (i) the
                              Applicable Percentage for each Corresponding Slide
                              or VETTEST slide, as the case may be, BY (ii) the
                              average price such Corresponding Slide is sold to
                              distributors by OCD, or the price then in effect
                              under this Agreement for a VETTEST slide, as the
                              case may be and THEN (iii) aggregating the total
                              of such multiplication calculations for all
                              chemistries listed on SCHEDULE 5 (as such SCHEDULE
                              5 may from time to time be revised).

All references to currency in this Agreement shall mean U.S. Dollars unless
otherwise specifically indicated.

2. EFFECT OF AGREEMENT

   2.01   This Agreement shall become effective upon the Commencement Date.

3. OCD RIGHT OF FIRST REFUSAL

   3.01   IDEXX shall not enter into any negotiations with any third party
          concerning human biomedical applications of the VETTEST analyzer
          without first offering to OCD the opportunity to negotiate marketing
          rights for the human biomedical applications of the VETTEST analyzer.
<PAGE> 4
4. AGREEMENT TO SUPPLY

   4.01   Subject to the terms and conditions of this Agreement, OCD undertakes
          to manufacture for IDEXX and to supply to IDEXX VETTEST slides,
          VETTEST tips and Vetrol controls.  OCD shall supply VETTEST slides in
          compliance with the VETTEST Slide Quality Assurance Procedures set
          out in SCHEDULE 4.

5. FORECASTS, COMMITMENTS AND ORDERS

   5.01   Attached hereto as SCHEDULE 4 are aggregate Purchase Commitments by
          IDEXX and IDEXX US for VETTEST slides for calendar years 1999 through
          and including 2006.  The Purchase Commitments constitute the
          aggregate anticipated minimum aggregate purchase quantities by IDEXX
          and IDEXX US for single chemistry VETTEST slides and PANELS/PROFILES
          slides in the indicated calendar years.  For calendar years 2007
          through and including 2010, IDEXX shall advise, or shall cause IDEXX
          US to advise, OCD of the aggregate Purchase Commitment for IDEXX and
          IDEXX US for each such year not later than October 1 of the preceding
          year, and upon receipt by OCD, such Purchase Commitments shall be
          deemed to be incorporated into SCHEDULE 4.  IDEXX's and IDEXX US's
          aggregate Purchase Commitment for the period 2007 through and
          including 2010 shall be not less than *********** slides.

          During each of calendar years 2000 through and including 2002, IDEXX
          and IDEXX US shall purchase, in the aggregate, not less than
          ************* *********** single slides; during each of calendar years
          2003 through and including 2006, IDEXX and IDEXX US shall purchase, in
          the aggregate, not less than ****************** single slides; and
          during each of the calendar years 2007 through and including 2010,
          IDEXX and IDEXX US shall purchase, in the aggregate, a minimum number
          of single slides equal to **** of the total Purchase Commitment for
          such year.

          Failure by IDEXX and IDEXX US to purchase, in the aggregate, at least
          the indicated Purchase Commitment quantities of each type of slides in
          any year may subject IDEXX to the requirement to make a payment to OCD
          as set forth in sub-Clause 5.02 below, but such failure shall in no
          event otherwise be deemed to be a breach of this Agreement.

   5.02   If IDEXX and IDEXX US fail to purchase in the aggregate the quantities
          of slides set forth as Purchase Commitments on SCHEDULE 4 in a
          particular calendar year, unless there has been a Material Adverse
          Change (as defined in the following paragraph) IDEXX shall pay, or
          shall cause IDEXX US to pay, to OCD within 30 days after the end of
          such calendar year ***** of the product of (i) the number of each type
          of slides (single or PANELS/PROFILES) by which IDEXX and IDEXX US have
          in the aggregate fallen short of the Purchase Commitment and (ii) the
<PAGE> 5
          lowest per-slide price for the applicable type of slides under either
          of the Agreements.

          For the purposes of this sub-Clause 5.02, "MATERIAL ADVERSE CHANGES"
          shall mean material changes in the veterinary clinical chemistry
          markets which result from (a) non-invasive diagnostic testing other
          than any such testing which is introduced by IDEXX or its affiliates,
          (b) invasive diagnostic testing other than any such testing which is
          introduced by IDEXX or its affiliates, (c) the eradication of one or
          more diseases, or the development of new disease therapies, treatments
          or diagnostics, which significantly reduces demand for veterinary
          clinical chemistry testing, (d) decreased commitment by or ability of
          OCD to supply VETTEST or VITROS slides, and (e) the availability in
          one or more significant markets of slides compatible with the VETTEST
          analyzer from sources other than IDEXX or its affiliates, which
          availability is not promptly enjoined or otherwise terminated by OCD.
          Whether a Material Advance Change has occurred will be determined by
          reference to the effect of a change in the veterinary clinical
          chemistry market on IDEXX and IDEXX US taken as a whole, and not on
          either individually.

          The parties shall discuss in good faith any assertion by IDEXX or
          IDEXX US that a Material Adverse Change has occurred or is continuing.
          If the parties agree that a Material Adverse Change has occurred or is
          continuing, they shall negotiate in good faith with respect to
          appropriate reductions in Purchase Commitments, VETTEST slide prices
          (including single and PANELS/PROFILES slides) and/or amounts which
          would otherwise be payable pursuant to the first sentence of this sub-
          Clause 5.02 to appropriately allocate the effects of such Material
          Adverse Change on the parties.

   5.03   IDEXX shall place orders for slides at least three calendar months
          prior to the required delivery date.  Unless otherwise agreed between
          the parties in any particular case, orders for slides shall be placed
          by IDEXX three times per year and each order shall specify a business
          day delivery date for each delivery.

   5.04   Not later than October 1 of each calendar year  commencing October 1,
          1999, IDEXX shall notify, or shall cause IDEXX US to notify, OCD of
          the aggregate forecasted requirements of IDEXX and IDEXX US for the
          subsequent year for each of the VETTEST slides (single slides and
          PANELS/PROFILES slides) (each such notification, a "PURCHASE
          FORECAST"), and the aggregate order quantities in the subsequent year
          for each of the VETTEST slides shall be within +/- 25% of such
          aggregate Purchase Forecast unless the parties otherwise agree.
          As long as slide orders are within the indicated range of +/-
          25% of the applicable Purchase Forecast, OCD shall deliver the
          slides in accordance with the orders.  The Purchase Forecasts
          constitute non-binding forecasts, which shall be the basis for
          determining IDEXX's, and IDEXX US's aggregate quarterly cash rebate
          pursuant to sub-Clause 7.03 below.
<PAGE> 6
   5.05   In the event that IDEXX or IDEXX US in any year notifies OCD that they
          wish to order quantities which exceed the quantities mentioned in sub-
          Clause 5.04 above by more than 25%, OCD will endeavor to supply the
          excess quantities and notify IDEXX or IDEXX US, as appropriate, of the
          extent of its ability to so supply.

   5.06   It is understood and agreed that orders for the VETTEST slides shall
          include only those chemistries set forth in SCHEDULE 5 hereto.  In the
          event that a chemistry listed in SCHEDULE 5 should become known by OCD
          to be unavailable at any future date during the Term, OCD will so
          notify IDEXX at the earliest practicable date and will cooperate with
          IDEXX to ameliorate the possible adverse effects upon IDEXX of such
          unavailability.

   5.07   Order and delivery of VETTEST slides (including PANELS/PROFILES) shall
          be made in multiples of 100 boxes. The number of orders and deliveries
          shall be limited to three in each year unless otherwise agreed to in
          writing by the parties.  Order and delivery of the VETTEST tips shall
          be made in multiples of 10,000 tips (20 cartons each containing
          500 tips).  The number of orders and deliveries of the VETTEST tips
          and Vetrols shall be limited to two in each year. OCD shall deliver
          the VETTEST tips and Vetrols in the ordered quantities in each year.

6. DELIVERY

   6.01   Following acknowledgement by OCD of each order placed by IDEXX and on
          or before the delivery due date, OCD shall complete delivery of the
          appropriate quantity of slides and tips within +/- 10%. Deviations of
          delivery quantities from order quantities within the +/- 10% range may
          be compensated by IDEXX in the first subsequent order placed, subject
          to Clause 5.  In the event of a price increase for one or more of the
          VETTEST slides, such compensating quantity of such slides shall be
          processed at the previous lower price.

   6.02   Order and delivery for all purchases hereunder shall be F.O.B.
          Rochester, New York, USA.

   6.03   Unless otherwise advised in writing by OCD to IDEXX, OCD shall pack
          the VETTEST slides in accordance with OCD's standard shipping
          configuration which is known to IDEXX and which at the Commencement
          Date contains approximately 60 cases per pallet, each case containing
          100 boxes of slides.
<PAGE> 7
7. PRICES

   7.01   The initial prices for each of the VETTEST slides (including the
          PANELS/ PROFILES) shall be as set forth in SCHEDULE 5 hereto.  Such
          prices are broken out to provide prices for each individual product
          code for the following geographic region (additional regions may be
          added, and changes within regions may be agreed to, from time to time
          in writing by the parties):

          European--Australia, Europe, New Zealand, South Africa;

          IDEXX agrees that OCD may audit IDEXX's books and records to verify
          sales of VETTEST slides in any region.

   7.02   The prices set forth in SCHEDULE 5 shall remain in effect for orders
          placed through December 31, 2000.  Thereafter, the prices may be
          adjusted upon 90 days written notice to IDEXX, subject to the next
          sentence of this sub-Clause 7.02, effective as of January 1 of each
          year for orders placed on or after that date by an amount not to
          exceed *** of the annual change (increase or decrease) in the US
          Consumer Price Index as reported by the United States Bureau of Labor
          Statistics, for the calendar year since the immediately preceding
          price adjustment.  Notwithstanding the preceding sentence, if the
          aggregate quantities of the single slide and PANELS/PROFILES slide
          purchases of IDEXX and IDEXX US exceed **** of the Purchase Forecasts
          for a particular year as set forth on SCHEDULE 4, there shall be no
          price increase for the immediately succeeding year.

   7.03   Beginning with slide purchases made during calendar year 2000 (which,
          for the avoidance of doubt, shall not include any slides shipped by
          OCD in calendar year 2000 to fulfill IDEXX's and IDEXX US's total
          aggregate 1999 purchase order of ***************), IDEXX shall be
          entitled to receive its Proportionate Share (based on sales during a
          calendar year) of a cash rebate in the amount set forth below if the
          total aggregate slide purchases by IDEXX and IDEXX US, in any calendar
          year, exceed the aggregate quantities set forth below:

         Annual Slide Purchases    Incremental Cash Rebate -
                                      % Off Purchase Price
             **************                   ***
         ***********************              ***
         ***********************              ***
         ***********************              ***
         ***********************              ***
         ***********************              ***
          ********************                ***

          The rebate amounts set forth above constitute a percentage reduction
          in the purchase price of any slides (including both single slides and
<PAGE> 8
          PANELS/PROFILES slides) purchased above the corresponding quantity.
          The percentage amounts are incremental (as opposed to cumulative) and
          relate only to the quantities set forth opposite it.  For example, if
          IDEXX and IDEXX US were to purchase, in the aggregate, **********
          slides in any one calendar year, they would not be entitled to a ***
          price reduction on all slides that they purchased in such year,
          rather, they would be entitled to receive (i) ** purchase price
          reduction on the first ********* slides purchased, (ii) a *** purchase
          price reduction on all slides purchased over **********, up to and
          including **********, (iii) an *** purchase price reduction on all
          slides purchased over ****************** up to and including
          **********, and (iv) a *** purchase price reduction on all slides
          purchased over ****************** up to and including the **********
          slides that they purchased.  The foregoing notwithstanding, it is
          understood and agreed that if IDEXX and IDEXX US do not, in the
          aggregate, achieve the aggregate Purchase Commitments set forth in
          Section 5 in any calendar year, then they shall not be entitled to
          receive a rebate for such year.

          In the beginning of each calendar year, beginning with calendar year
          2000, OCD shall calculate an estimated Effective Rebate Rate (the
          "ESTIMATED REBATE RATE") based on the lesser of (i) IDEXX's and IDEXX
          US's aggregate Purchase Forecast for such year and (ii) **** of the
          total aggregate number of slides that IDEXX and IDEXX US together
          purchased in the immediately preceding calendar year.  Not later than
          thirty (30) days after the end of each of the first three calendar
          quarters in any calendar year (or thirty days after IDEXX and IDEXX US
          complete payment in full for slides purchased during such quarter, if
          later), OCD shall pay to IDEXX its Proportionate Share (based on
          purchases during the preceding quarter) of an amount equal to the
          aggregate estimated rebate payment that IDEXX and IDEXX US would
          together be entitled to receive in such quarter (the "ESTIMATED REBATE
          PAYMENT").  The Estimated Rebate Payment for any quarter shall be
          calculated by (i) multiplying the Estimated Rebate Rate in effect
          during such quarter by the total aggregate purchase price for the
          VETTEST slides purchased by IDEXX and IDEXX US during such quarter and
          (ii) subtracting from such amount an amount equal to *** of the total
          calculated in clause (i) above.  The foregoing notwithstanding, if, in
          any calendar year, (i) IDEXX's and IDEXX US's total aggregate slide
          orders for the immediately preceding calendar year were less than ***
          of their aggregate Purchase Forecast for such preceding calendar year
          or (ii) OCD determines, in its reasonable discretion, at anytime after
          the end of the second calendar quarter of such calendar year, that
          IDEXX and IDEXX US are reasonably unlikely to meet their aggregate
          Purchase Forecast for such year, then OCD shall have the right to
          recalculate the Estimated Rebate Rate based on IDEXX's and IDEXX US's
          aggregate Purchase Commitment for such year (such recalculated rate
          being hereinafter referred to as the "NEW ESTIMATED REBATE RATE").  If
          OCD elects to recalculate the Estimated Rebate Rate pursuant to the
          immediately preceding sentence, (i) OCD shall notify IDEXX in writing
          which notice shall set forth the New Estimated Rebate Rate, (ii) OCD
          shall calculate all remaining quarterly Estimated Rebate Payments
          (which may include the Estimated Rebate Payment for the second
<PAGE> 9
          calendar quarter) using the New Estimated Rebate Rate and (iii) all
          such Estimated Rebate Payments shall be made in accordance with this
          sub-clause 7.03, except that such Estimated Rebate Payments shall be
          less the amount by which the aggregate Estimated Rebate Payments
          received by IDEXX and IDEXX US  during the then current calendar year
          exceed the aggregate Estimated Rebate Payments they would have
          received during such calendar year if the New Estimated Rebate Rate
          were in effect from the first day of such calendar year.

          Notwithstanding any provision in this Agreement to the contrary, OCD
          shall not be required to pay to IDEXX its Proportionate Share of any
          Estimated Rebate Payments in any calendar year if (A) any amounts
          payable to OCD from IDEXX pursuant to this Agreement are overdue,
          unless such amounts are being disputed in good faith by IDEXX, or (B)
          OCD determines in its reasonable judgment that IDEXX and IDEXX US are
          reasonably unlikely to meet their aggregate Purchase Commitments for
          such year.  In the case of clause (B) above, OCD shall have the right
          to make such determination at any time after the end of the second
          calendar quarter of any calendar year (or at the beginning of such
          calendar year if IDEXX's and IDEXX US's aggregate Purchase Forecast
          for such year is less than their aggregate Purchase Commitment for
          such year) provided that OCD has consulted with IDEXX and given IDEXX
          an opportunity (which opportunity shall be available for a period of
          not less than 5 business days nor more than 10 business days) to
          demonstrate its and IDEXX US's intent and ability to meet their
          aggregate Purchase Commitments for such year.  For the avoidance of
          doubt, OCD's obligation to make any Estimated Rebate Payments shall be
          suspended during the period referred to in the immediately preceding
          sentence and the days in such period shall not be counted when
          determining the date by which the next scheduled Estimated Rebate
          Payment is due and payable.  If, after fulfilling the requirements set
          forth in this paragraph, OCD makes the determination described in
          clause (B) above, OCD (i) shall promptly notify IDEXX in writing of
          its determination and (ii) shall thereafter have the right to cease
          making Estimated Rebate Payments for the remainder of such calendar
          year.

          Not later than thirty (30) business days after the end of the last
          calendar quarter of any calendar year (or thirty days after IDEXX and
          IDEXX US complete payment in full for slides purchased during such
          quarter, if later), OCD shall pay to IDEXX its Proportionate Share
          (based on purchases during such calendar year) of the amount by which
          (i) the Effective Rebate Rate multiplied by the total aggregate
          purchase price for VETTEST slides purchased by IDEXX and IDEXX US
          during such calendar year exceeds (ii) the total aggregate amount of
          the Estimated Rebate Payments made by OCD to IDEXX and IDEXX US during
          such calendar year.  If the amount in clause (ii) above exceeds the
          amount in clause (i) above, OCD shall deliver to IDEXX a written
          notice of such fact (a "REIMBURSEMENT NOTICE") and IDEXX shall pay to
          OCD, within thirty (30) days of receipt of such notice an amount in
          cash equal to its Proportionate Share of the amount of such excess.
<PAGE> 10
          Notwithstanding the foregoing, (i) if any amounts payable to OCD from
          IDEXX pursuant to this Agreement are overdue, other than amounts that
          are being disputed in good faith by IDEXX, then OCD shall be entitled
          to withhold such overdue amount (plus any accrued interest) from any
          rebate payments to which IDEXX may be entitled and (ii) if IDEXX and
          IDEXX US do not achieve their aggregate Purchase Commitment in any
          given calendar year, then IDEXX shall return all Estimated Rebate
          Payments received from OCD for such year no later than thirty (30)
          days after the end of such calendar year.

          Any overdue payments by OCD or IDEXX of any amounts owed to the other
          pursuant to this sub-clause 7.03 shall bear interest at a rate per
          annum equal to *** **********.  Such interest shall be payable at the
          same time as the payment to which it relates and shall be calculated
          daily on the basis of a year of 365 days and the actual number of days
          elapsed.

          OCD shall prepare a remittance advice to accompany each rebate payment
          (or Reimbursement Notice), which shall set forth the reporting period
          for which the payment is made (or demanded) and a summary sheet which
          shall detail OCD's calculation of the rebate (or reimbursement).  If
          IDEXX disagrees with the rebate or reimbursement calculation, IDEXX
          shall promptly notify OCD, and the parties, together with IDEXX US if
          appropriate, shall review the calculations together in good faith to
          agree on any appropriate corrections or adjustments.

          An illustrative representation of the foregoing rebate calculation
          methodology is attached hereto as SCHEDULE 6.

   7.04   OCD agrees to provide to IDEXX on a regular basis during the Term the
          current average price at which OCD sells each Corresponding Slide to
          its distributors.  At IDEXX's request, but not more often than once
          per calendar year, OCD shall calculate the Weighted Average List Price
          for all Corresponding Slides.  If the Weighted Average List Price for
          VETTEST SLIDES purchased by IDEXX and its affiliates exceeds the
          Weighted Average List Price for Corresponding Slides by more than 10%,
          then all of the VETTEST single and PANELS/PROFILES slide prices to
          IDEXX shall be reduced by the percentage by which the Weighted Average
          List Price for Corresponding Slides is less than the Weighted Average
          List Price for VETTEST slides purchased by IDEXX and its affiliates.
          Such reduction shall be effective from the later of (i) twelve months
          prior to the date on which IDEXX requests OCD to calculate the
          Weighted Average List Price for Corresponding Slides or (ii) the date
          on which the average price at which OCD sells each Corresponding
          Slides to its distributors resulted in the Weighted Average List Price
          for VETTEST Slides exceeding the Weighted Average List Price for
          Corresponding Slides by more than 10%.
<PAGE> 11
          Either party may request that an accounting firm of international
          reputation, other than the principal accounting firm of either party,
          audit the other's books and records to verify the Weighted Average
          List Price and actual unit volume sales of Corresponding Slides or
          VETTEST slides, as the case may be.  Such auditor shall report to the
          parties only (a) the Weighted Average List Price and (b) the
          Applicable Percentage for each Corresponding Slide or VETTEST slide,
          as the case may be.  The prices and percentages contained in such
          auditor's report shall be deemed to be the Weighted Average List Price
          and Applicable Percentages for Corresponding Slides or VETTEST slides,
          as the case may be, respectively, hereunder until modified in
          accordance with this sub-Clause 7.04.  The fees and expenses of such
          auditor shall be borne equally by the parties.

   7.05   If OCD is entitled to a price increase pursuant to sub-Clause 7.02 and
          IDEXX is entitled to a price decrease pursuant to sub-Clause 7.04, the
          net percentage increase or decrease in price shall be used to
          calculate slide prices for the next calendar year.

8. INVOICES AND PAYMENT

   8.01   OCD shall invoice IDEXX in respect of each order for the VETTEST
          slides upon completion by OCD of the delivery of such order.  Each
          order shall be billed by OCD under one invoice in US dollars and
          payment shall be made by IDEXX in US dollars not later than thirty
          (30) days following the date of invoice.

9. EXCLUSIVITY

   9.01   OCD undertakes during the Term not to sell or otherwise supply VETTEST
          slides, or VITROS slides bar-coded for use in the VETTEST Analyser
          (whether or not finished or complete) to any person, firm or company
          other than IDEXX or its affiliates.

   9.02   IDEXX undertakes during the Term to purchase slides for use in the
          VETTEST analyzer only from OCD or affiliates of IDEXX, to the
          extent that the desired chemistries are available from OCD.

   9.03   In view of IDEXX's expertise in the veterinary market, IDEXX shall
          concentrate its efforts on distributing VETTEST slides to customers
          in the veterinary market.

   9.04   This Agreement shall not in any way restrict OCD from selling VITROS
          slides to any customer in or outside the veterinarian market.

   9.05   This Agreement shall not restrict OCD from developing an analyzer
          other than the DT60 for sale by OCD to the veterinarian market for
          use with VITROS slides.
<PAGE> 12
   9.06   This Agreement shall not restrict OCD from selling VITROS slides to
          other manufacturers wishing to develop and market an analyzer for use
          with VITROS slides for applications outside the veterinarian market.

   9.07   In view of OCD's expertise in the human biomedical market, OCD shall
          concentrate its efforts on distributing VITROS slides to customers in
          the human biomedical market.

10. MARKETING ARRANGEMENTS

   10.01  IDEXX will be responsible for all marketing arrangements for the
          VETTEST analyzer and the VETTEST slides.  IDEXX may appoint any of
          OCD's medical/surgical dealers as distributors of or agents for the
          VETTEST analyzer and the VETTEST slides but will not be obliged to do
          so.

   10.02  IDEXX will be responsible for the establishment of dealer performance
          criteria for all dealers including OCD's medical/surgical dealers (if
          any are appointed by IDEXX as distributors of the VETTEST analyzer and
          the VETTEST slides).

   10.03  IDEXX will keep OCD informed of and consult with OCD as to marketing
          arrangements for the VETTEST analyzer and the VETTEST slides but will
          not be obligated to OCD beyond the terms of this Agreement in
          connection with such marketing arrangements.

11. SALES SUPPORT

   11.01  IDEXX will be responsible for all necessary sales support for the
          VETTEST analyzer and the VETTEST slides.

   11.02  OCD's sole obligation in respect of sale support shall be at its own
          expense to assist IDEXX in resolving specific problems exhibited by
          the VETTEST slides.

12. TESTING

   12.01  OCD shall disclose to IDEXX its quality assurance procedures used in
          final evaluation of the VETTEST slides and full particulars thereof
          as set out in the VETTEST Slide Quality Assurance Procedures forming
          SCHEDULE 4 to this Agreement.  OCD shall operate such quality
          assurance procedures in accordance with SCHEDULE 4.

   12.02  Upon prior written notice from IDEXX, OCD shall grant authorized
          representatives of IDEXX access to that part of OCD production
          facilities which conducts final evaluation of the VETTEST slides for
          the purpose of enabling such representatives to monitor the
          application by OCD of the VETTEST Slide Quality Assurance Procedures
          set out in SCHEDULE 4.  Such access shall be granted by OCD to IDEXX
<PAGE> 13
          and IDEXX US no more than twice in any twelve-month period, and shall
          be limited to such final evaluation facilities.

13. BAR CODING AND PACKAGING

   13.01  The VETTEST slides shall be printed by OCD with special bar coding for
          use in the VETTEST analyzer.

   13.02  OCD shall package the VETTEST slides and tips in the physical manner
          as used for the VITROS slides and tips at the time of packaging of the
          VETTEST slides and tips.  In the event of a change in VITROS slide or
          tip packaging which has an impact on the VETTEST slide or tip
          packaging, OCD shall notify IDEXX as early as practicable of the
          relevant particulars of such change.

   13.03  OCD shall furnish on a timely basis to IDEXX drawings and information
          describing the geometry and the materials of labels for the VETTEST
          slide wrap, the slide and tip cartons, and the case for the purpose of
          developing the label content and art work for such packaging.  IDEXX
          shall be responsible for developing all such label content and
          artwork, which shall require the approval of OCD.  The parties shall
          cooperate to settle the form and appearance of label content and
          artwork which, save as authorized by sub-Clause 14.01 below, shall not
          include any trademarks, trade names, or trade dress of OCD.  IDEXX
          shall furnish such label content and art work to OCD on a timely
          basis, and such label content and art work shall not be changed at any
          time during the Term without the prior agreement of the parties.

   13.04  OCD shall be responsible for incorporating the artwork described in
          sub-Clause 13.03 above into the packaging of the VETTEST slides and
          tips.

14. TRADE MARKS AND TRADE NAMES

   14.01  OCD expressly authorizes IDEXX to use the phrase "manufactured by
          Ortho-Clinical Diagnostics, Inc. for IDEXX (IDEXX ADDRESS)" on
          packaging of the VETTEST slides.  No other uses of OCD's trademarks,
          trade names or trade dress are authorized by this Agreement.

   14.02  IDEXX shall neither acquire, nor claim any right, title or interest in
          or to any of OCD's trade marks or trade names by virtue of this
          Agreement or through advertising and sale of the VETTEST analyzer or
          the VETTEST slides or otherwise.

15. PATENT INDEMNITIES

   15.01  OCD shall hold IDEXX harmless for all loss, damage, cost and expense
          whatsoever, including legal fees, patent attorney's fees and court
<PAGE> 14
          costs that IDEXX may incur or become liable for as a result of any
          action, suit or claim alleging infringement of any patent held by a
          third party arising form the use and/or sale of the VETTEST slides or
          tips to the extent that such action, suit, or claim relates in a
          material way to the specification for the VITROS slides or tips or to
          any OCD patent.  If as a result of any judgment or settlement it is
          determined that a claim or claims of a third party patent is infringed
          by the use and/or sale of the VETTEST slides or tips as aforesaid and
          IDEXX is required to make any payments to any third party as a result
          thereof, IDEXX may off-set all such payments against any present
          and/or future payments to be made to OCD hereunder.

   15.02  IDEXX shall hold OCD harmless for all loss, damage, cost and expense
          whatsoever, including legal fees, patent attorney's fees and court
          costs that OCD may incur or become liable for as a result of any
          action, suit or claim alleging infringement of any patent held by a
          third party arising from either the manufacture, use or sale of the
          VETTEST slides or tips to the extent that the VETTEST slides or tips
          differ from the VITROS slides or tips or the manufacture use or sale
          of the VETTEST analyzer.

16. WARRANTY, LIABILITY AND INDEMNIFICATION

   16.01  OCD hereby warrants that:

          (a)  the VETTEST slides delivered to IDEXX shall be in compliance with
               SCHEDULE 4, and

          (b)  the packaging of the VETTEST slides and tips shall be undamaged
               at delivery.

   16.02  In the event of a breach on the part of OCD of sub-Clause 16.01
          above, OCD's liability shall be limited to the replacement of the
          VETTEST slides or tips found to be defective, including shipping costs
          for return of defective slides or tips and delivery of replacement
          slides or tips.

   16.03  OCD's liability as stated in sub-Clause 16.02 shall be subject to the
          following conditions:

          (a)  IDEXX shall notify OCD promptly of any noncompliance contrary to
               sub-Clause 16.01(a) or damage contrary to sub-Clause 16.01(b).

          (b)  IDEXX and its transferees shall not alter or modify the VETTEST
               slides or packaging of the VETTEST slides or tips without prior
               approval of OCD.
<PAGE> 15
   16.04  Except as provided in this Clause 16 there are no other warranties,
          express or implied, including warranties for fitness for any
          particular use of merchantability.

   16.05  Subject to Clause 15, IDEXX hereby indemnifies and holds harmless OCD
          from any against any claim, loss, damage, or expense (including
          attorney's fees) with respect to any physical injury to persons,
          animals or property arising out of or in connection with IDEXX's use
          or sale of the VETTEST analyzer or the VETTEST slides, including any
          claimed infringement of any trademark (except OCD's own trademark),
          trade dress, trade secret, or copyright, and IDEXX shall assume the
          defense of any action or suit brought against OCD and the disposition
          of such action or suit.  IDEXX shall notify OCD at the commencement of
          any such action or suit and in the event of any adverse judgment which
          prevents the sale or use of the VETTEST analyzer or the VETTEST
          slides.  In addition, IDEXX shall obtain advance written approval of
          OCD prior to entering into any settlement of any such action or suit,
          which limits OCD's rights under this Agreement.

17. SECRECY

   17.01  Each of IDEXX and OCD agrees to protect confidential information
          disclosed to it upon terms set out in SCHEDULE 2 attached hereto.

18. PERIOD OF AGREEMENT

   18.01  This Agreement shall commence on the Commencement Date and, subject to
          satisfaction of the quantity requirements set out in Clause 5 above,
          shall continue throughout the Term.

   18.02  Between twelve (12) and six (6) calendar months prior to the end of
          the Term, the parties shall meet to extend this Agreement.  Such
          extension is to be for a term of five (5) years and include provision
          for further extension.

19. TERMINATION

   19.01  This Agreement may be terminated by either party in any of the
          following events:

          (a)  If the other party is guilty of gross or persistent breaches of
               the terms of this Agreement, which breaches are not remedied to
               the satisfaction of the other party after ninety (90) days notice
               in writing to do so.  Any such breach shall entitle the innocent
               party to terminate this Agreement by notice in writing which
               notice shall be effective at the end of ninety (90) days
               following the date of such notice.

          (b)  If the other party becomes insolvent or compounds with its
               creditors or goes into liquidation (other than for the purposes
<PAGE> 16
               of corporate reorganization) then the innocent party may
               terminate this Agreement by notice in writing which shall have
               immediate effect.

   19.02  Changes in the equity ownership or corporate reorganizations of either
          party shall not be grounds for termination of this Agreement, except
          that OCD may terminate this Agreement at its sole discretion in the
          event that more than 40% of the outstanding capital stock of IDEXX is
          transferred to a competitor of the diagnostic division of OCD.

   19.03  OCD shall have the right to terminate this Agreement upon five years'
          prior written notice to IDEXX in the event OCD elects to cease the
          manufacture and sale of dry slide diagnostic products.  The minimum
          purchase obligations of IDEXX shall terminate upon delivery of such a
          notice of termination.

   19.04  IDEXX shall have the right to terminate any obligations it may have
          pursuant to sub-Clauses 5.01 and 5.02 and SCHEDULE 4 of this Agreement
          upon prior written notice to OCD of four full calendar years.  Upon
          the commencement of the first full calendar year of a notice period
          pursuant to the preceding sentence, sub-Clauses 7.03, 7.04 and 7.05
          and the last sentence of sub-Clause 7.02 shall be terminated, except
          for any previously accrued obligation of OCD to provide a credit
          rebate pursuant to sub-Clause 7.03 for the immediately preceding
          calendar year.

   19.05  This Agreement shall terminate automatically upon any termination of
          the US Agreement.

20. FORCE MAJEURE

   20.01  In the event of force majeure, OCD shall be entitled to extend the
          time of delivery for any outstanding order by the period during which
          such force majeure prevails, plus a reasonable start-up period.  Force
          majeure shall include any circumstances beyond OCD's control.

   20.02  Upon the cessation of the force majeure event, then without prejudice
          to any lawful reduction in the obligations of OCD by reason of the
          occurrence of such force majeure, OCD shall use its best endeavors to
          make up any lost time.

21. GOVERNING LAW

   21.01  The construction, validity and performance of this Agreement shall be
          governed in all respects by the laws of the State of New York, USA.
<PAGE> 17
22. SEVERABILITY

   22.01  Any term or provision of this Agreement that is invalid or
          unenforceable in any situation in any jurisdiction shall not affect
          the validity or enforceability of the remaining terms and provisions
          hereof or the validity or enforceability of the offending term or
          provision in any other situation or in any other jurisdiction.  If the
          final judgment of a court of competent jurisdiction declares that any
          term or provision hereof is invalid or unenforceable, then the parties
          agree that the court making the determination of invalidity or
          unenforceability shall have the power to reduce the scope, duration,
          or area of the term or provision, to delete specific words or phrases,
          or to replace any invalid or unenforceable term or provision with a
          term or provision that is valid and enforceable and that comes closest
          to expressing the intention of the invalid or unenforceable term or
          provision, and this Agreement shall be enforceable as so modified
          after the expiration of the time within which the judgment may be
          appealed.

23. WAIVERS

   23.01  Failure of either party to this Agreement to insist upon strict
          observance or compliance with all its terms and conditions in one or
          more instances shall not be deemed to be a waiver of its right to
          insist upon such observance or compliance with such term or condition
          or with any other terms or conditions hereof in the future.

24. PRIOR AGREEMENTS; INTERPRETATION

   24.01  This Agreement shall take effect in substitution for all or any
          previous Agreements relating to the subject matter hereof whether the
          same are formal agreements or agreements that would be inferred from
          the parties' correspondence or conduct and all or any such agreements
          shall be deemed to have been terminated by mutual consent on the
          Commencement Date; provided, however, that nothing contained herein
          shall be deemed to modify or terminate the US Agreement, except that
          the Purchase Commitments and Purchase Forecasts referred to in
          Clause 5 and in SCHEDULE 4 of this Agreement and the US Agreement
          represent the aggregate commitments and forecasts of IDEXX and IDEXX
          US and not the individual commitments and forecasts of IDEXX US under
          the US Agreement or IDEXX under this Agreement.

25. ENTIRE AGREEMENT

   25.01  This Agreement constitutes the complete agreement of the parties
          concerning the arrangements between the parties and the parties shall
          not be liable for or bound in any manner by any representations,
          guarantees or commitments except as expressly provided herein.
<PAGE> 18
26. ALTERATION OR MODIFICATION

   26.01  No alteration, amendment or modification to this Agreement or the
          attached Schedules shall be of any force or effect unless in writing
          and signed by both parties, except that during the Term of this
          Agreement, SCHEDULES 3, 4 and 5 may from time to time be amended by
          written agreement signed by IDEXX and IDEXX US and the OCD Clinical
          Products' representative designated in Clause 29 of the Agreement.  No
          modification shall be effected by the acknowledgement or acceptance of
          purchase order forms or order confirmations or invoices or other
          documents containing different conditions.

27. ASSIGNMENT

   27.01  This Agreement shall not be capable of assignment by either party to a
          company of which it owns less than a majority or which owns less than
          a majority of the party save in the case of (i) an assignment at OCD's
          sole discretion as a result of OCD's divestiture of its VITROS
          business or (ii) a sale by IDEXX and IDEXX US of all or substantially
          all of their assets to an entity which is not a competitor of the
          diagnostic division of OCD.

28. GOVERNING LANGUAGE

    28.01 [Reserved]

29. NOTICES

   29.01  Any notice, statement or other communication to be given by one party
          to the other hereunder may be given by registered mail, airmail or
          telex to the party concerned at the addresses set out below:

          Ortho-Clinical Diagnostics, Inc.
          1001 US Highway 202
          Raritan, New Jersey 08869, USA
          For the attention of: Vice President, Sales & Marketing

          With a copy to:
          Johnson & Johnson
          One Johnson & Johnson Plaza
          New Brunswick, New Jersey 08933, USA
          For the attention of: Office of General Counsel
<PAGE> 19
          IDEXX Europe B.V.
          Koolhovenlaan 20
          1119 NE - Schiphol-Rijk
          The Netherlands
          For the attention of: IDEXX Director of European
          Finance and Administration

          With a copy to:
          IDEXX Laboratories, Inc.
          One IDEXX Drive
          Westbrook ME 04092
          For the attention of: President and Office of
          General Counsel

          It is understood that by written notice to IDEXX signed by OCD, OCD
          may from time to time during the Term of this Agreement change its OCD
          Clinical Products representative designated (i) to receive notice
          hereunder and (ii) to amend certain Schedules hereto as set forth in
          Clause 26 of this Agreement.

   29.02  Any notice, payment or communication so given or made shall be deemed
          to have been received at the time when in the ordinary course of
          transmission the same should have reached its destination.  Either
          party may change its address for the purpose of this Agreement by
          giving notice of such change to the other party pursuant to the
          provisions of this Clause.  For purposes of this Clause 29.02, notice
          given by OCD to IDEXX US under the US Agreement shall be deemed given
          to IDEXX.

30. DISPUTES

          Any and all disputes, controversies or differences between the parties
          hereto arising out of or in relation to or in connection with this
          Agreement, or the breach hereof, which cannot be settled amicably
          through negotiations between the parties hereto, shall be submitted to
          and settled by arbitration.  Such arbitration shall be conducted in
          New York, New York in accordance with the rules then obtaining of the
          American Arbitration Association ("AAA") by a panel of three
          arbitrators selected from the National Panel of Arbitrators of the
          AAA.  If the parties cannot agree on three arbitrators, the AAA shall
          select one or more arbitrators as necessary to complete the panel.
          Reasonable discovery shall be permitted in connection with the
          arbitration proceeding, and the arbitrators shall apply the
          substantive laws of the State of New York except that the
          interpretation and enforcement of this arbitration provision shall be
          governed by the Federal Arbitration Act.  Any award rendered in any
          such arbitration shall be final and binding upon both parties hereto
          and judgment upon the award rendered by the panel of arbitrators may
          be entered in any court having jurisdiction over the party against
          whom the award is to be enforced.  Each party shall bear its own costs
          in connection with any such arbitration, and any costs of the
          arbitrators or the AAA shall be borne equally by the parties.  The
<PAGE> 20
          arbitrators shall have no authority to assess or award punitive,
          incidental or consequential damages, and each party hereby waives its
          rights to any such damages.

31. 1999 REBATE

          If during calendar year 1999 IDEXX and IDEXX US sell worldwide, in the
          aggregate, any of the total slide volumes set forth below (counting
          both single slides and PANELS/PROFILES slides), IDEXX shall be
          entitled to a cash rebate in the amount of its Proportionate Share
          (based on sales during 1999) of the amount set forth opposite such
          sales volume:

           1999 Worldwide Slide Sales         Total Cash Rebate
                   ***********                        **
             ***********************             ************
             ***********************             ************
                   ***********                   ************

          The cash rebates above are not incremental or cumulative.  For the
          avoidance of doubt, the maximum rebate payment that IDEXX and IDEXX US
          could qualify for in the aggregate under this Clause 31 is
          ************.  IDEXX shall provide OCD with aggregate estimated sales
          volume information for calendar year 1999 not later than December 15,
          1999.  Not later than January 31, 2000, IDEXX shall provide OCD with
          aggregate 1999 actual slide sales volume information and, at any time
          that OCD may reasonably request, any other supporting information or
          documentation that OCD may reasonably request.  OCD shall calculate
          IDEXX's rebate accordingly, and shall remit to IDEXX its Proportionate
          Share of the total rebate amount not later than (i) February 15, 2000
          or, if later, (ii) five (5) business days after receipt by OCD, to its
          reasonable satisfaction, of all information which it requested
          pursuant to the immediately preceding sentence.  Any overdue payments
          by OCD shall bear interest at a rate per annum equal to **********.
          Such interest shall be payable at the same time as the payment to
          which it relates and shall be calculated daily on the basis of a year
          of 365 days and the actual number of days elapsed.

<PAGE> 21
   IN WITNESS WHEREOF and intending to be legally bound, the parties hereto have
caused this Agreement to be duly executed in duplicate by their respective
authorized representatives the day and year first written above.

ORTHO-CLINICAL                                IDEXX EUROPE B.V.
DIAGNOSTICS, INC.

By:  /s/ David A. Rowan                      By:   /s/ Yvonne van Kuijk
   -----------------------------                -----------------------------
     David A. Rowan,                               Yvonne van Kuijk,
     Vice President, Corporate Accounts            Managing Director

By:  /s/ Catherine M. Burzik
   -----------------------------
     Catherine M. Burzik
     President, Americas
     Ortho-Clinical Diagnostics, Inc.

By:  /s/ Bruce Given, M.D.
   -----------------------------
     Bruce Given, M.D.
     President, International
     Ortho-Clinical Diagnostics

<PAGE> 22

          SCHEDULE 1 - VETTEST(R) SLIDE QUALITY ASSURANCE PROCEDURES

INTRODUCTION

The following procedure constitutes a generic overview of the quality assurance
provisions for finishing of VITROS slides and applies in like manner to product
release for the VETTEST slides.

VETTEST SLIDE QUALITY ASSURANCE

VETTEST slides will be produced to the same quality standards as VITROS and DT
60 slides for OCD's human market unless otherwise agreed to by IDEXX.

BAR CODING

Bar code printing on the VETTEST slides will render the VETTEST slides
incompatible with use in VITROS analyzers.  OCD will reserve certain number
sequences for generation of the bar code patterns on the VETTEST slides.
<PAGE> 23
                                  SCHEDULE 2

     Section 1.  OBLIGATION TO KEEP INFORMATION CONFIDENTIAL.  Each party agrees
to hold, and will use its best efforts to cause its respective officers,
directors, employees, accountants, counsel, consultants, advisors and agents to
hold, in confidence all documents and information concerning the other party,
whether oral or written, furnished or made known to such party in connection
with the performance of the Supply Agreement; PROVIDED that no party shall be
required to keep any information confidential (i) if such party is compelled to
disclose such information by judicial or administrative process or by other
requirements of law and such party has provided prior written notice to the
other party and given such other party reasonable opportunity to contest
disclosure or (ii) to the extent such information can be shown to have been (A)
previously known to such party on a nonconfidential basis, (B) in the public
domain through no fault of such party, (C) later lawfully acquired from a third
party source or (D) independently developed by such party without reference to
confidential information.  The foregoing notwithstanding, any party may disclose
information concerning the other party to its officers, directors, employees,
accountants, counsel, consultants, advisors and agents in connection with its
performance of the Supply Agreement so long as such persons are informed by such
party of the confidential nature of such information and are directed by such
party to treat such information confidentially, it being understood and agreed
that such party shall be responsible for any failure to treat such information
confidentially by such persons.  The obligation of each party to hold any
information in confidence shall be satisfied if it exercises the same care with
respect to such information as it would to preserve the confidentiality of its
own similar information.

     Section 2.  DURATION.  These confidentiality provisions of this SCHEDULE 2
shall remain in effect for so long as the Supply Agreement is in effect and for
a period of three (3) years thereafter.

     Section 3.  GOVERNING LAW. The construction, validity and performance of
this SCHEDULE 2 shall be governed in all respects by the laws of the State of
New York, USA.

     Section 4.  NOTICES.  Any notices required to be given under this SCHEDULE2
shall be given in the manner specified by sub-Clause 29 of the Supply Agreement.

<PAGE> 24

                         SCHEDULE 3 - PANELS/PROFILES

The initial PANEL shall be the "Young Presurgical Panel" consisting of four sets
of the following six VETTEST slides:
<TABLE>
<CAPTION>
<S>                  <C>
BUN                  Urea Nitrogen
ALT                  Alanine aminotransferase
GLU                  Glucose
TP                   Total protein
CREA                 Creatinine
ALKP                 Alkaline phosphatase
</TABLE>
The initial PROFILES shall be the "General Health Profile" and the "Large Animal
Profile", each consisting of two sets of 12 VETTEST slides as follows:
<TABLE>
<CAPTION>
 General Health Profile                Large Animal Profile
 <S>    <C>                            <C>    <C>
 ALB    Albumin                        ALB    Albumin
 ALKP   Alkaline phosphatase           ALKP   Alkaline phosphatase
 ALT    Alanine Aminotransferase       AST    AST
 (SGPT)
 AMYL   Amylase                        Ca2+   Calcium
 Ca2+   Calcium                        CK     CK
 CHOL   Cholesterol                    GGT    Gamma GT
 CREA   Creatinine                     GLU    Glucose
 GLU    Glucose                        PHOS   Inorganic phosphate
 PHOS   Inorganic phosphate            LDH    LDH
 TBIL   Total bilirubin                MG     Magnesium
 TP     Total protein                  TP     Total Protein
 BUN    Urea Nitrogen                  BUN    Urea Nitrogen
</TABLE>
Packaging for the Young Presurgical Panels, the General Health Profiles and the
Large Animal Profiles has been previously agreed upon by the parties, and any
changes to the slide composition or packaging of the initial PANEL or the
initial PROFILES shall be negotiated in good faith and mutually agreed upon by
OCD and IDEXX.  The slide composition, packaging and initial pricing of any
additional PANELS/PROFILES shall be mutually agreed upon by OCD and IDEXX.
Unless otherwise agreed by the parties in writing with respect to one or more
specific PANELS or PROFILES, all purchases by IDEXX or IDEXX US of VETTEST
slides packaged as PANELS/PROFILES shall be credited against the Purchase
Forecasts and Purchase Commitments for such slides under this Agreement and the
US Agreement.

<PAGE> 25
                      SCHEDULE 4 - PURCHASE COMMITMENTS
<TABLE>
<CAPTION>
                      Year                 Minimum Slide Purchase
                      ----                 ----------------------
                                          Commitment (in millions)
                                          ------------------------
                      <S>                            <C>
                      1999                           **
                      2000                           **
                      2001                           **
                      2002                           **
                      2003                           **
                      2004                           **
                      2005                           **
                      2006                           **
                      2007              See Agreement sub-Clause
                      2008              5.01
                      2009
                      2010
</TABLE>

<PAGE> 26
<TABLE>
<CAPTION>
                       SCHEDULE 5 - PRODUCTS AND PRICES

                           (AS OF JANUARY 1, 1999)

                            Sales Region:  Europe
                            ---------------------

                           ***********************

Single Slides (Box of 25)         Catalog Number         European Pricing
-------------------------         --------------         ----------------
<S>                                  <C>                      <C>
Albumin                              ********                 ******
Alk Phos                             ********                 ******
ALT                                  ********                 ******
Ammonia                              ********                 ******
Amylase                              ********                 ******
AST                                  ********                 ******
Calcium                              ********                 ******
Cholesterol                          ********                 ******
CK                                   ********                 ******
Creatinine                           ********                 ******
ECO2                                 ********                 ******
Gamma GT                             ********                 ******
Glucose                              ********                 ******
LDH                                  ********                 ******
Lipase                               ********                 ******
Magnesium                            ********                 ******
Phosphorus                           ********                 ******
Total Bilirubin                      ********                 ******
Total Protein                        ********                 ******
Triglycerides                        ********                 ******
Urea Nitrogen                        ********                 ******
Uric Acid                            ********                 ******

Profile Slides (Box of 24)        Catalog Number         European Pricing
--------------------------        --------------         ----------------

General Health Profile               ********                 ******
Young Presurgical Panel              ********                 ******
Large Animal Profile                 ********                 ******

Other                             Catalog Number            WW Pricing
-----                             --------------            ----------

Vetrols                              ********                 ******
Tips                                 ********                 ******
</TABLE>

<PAGE> 27
                 SCHEDULE 6 - ILLUSTRATIVE REBATE CALCULATIONS

The Estimated Rebate Payments will be calculated for each of the first three
calendar quarters using the Effective Rebate Rate, as described more fully in
sub-clause 7.03 of the Agreement.  Any required adjustments will be made at the
end of the fourth calendar quarter, in accordance with sub-clause 7.03 of the
Agreement.

EXAMPLE:  THE AGGREGATE PURCHASE FORECAST FOR IDEXX AND IDEXX US IN A GIVEN
YEAR IS ** MILLION SLIDES; PRICING IS *****/SLIDE; BLENDED REBATE PERCENTAGE
RATE IS ****, AS FOLLOWS:

     ********************** million slides * *** = *** million slides
     *********************** million slides * *** = *** million slides
     *********************** million slides * *** = *** million slides
     *********************** million slides * *** = *** million slides
     ************************ million slides * *** = ***** million slides
     --------------------------------------------------------------------
     Total Slides Eligible for Rebate = ***** million slides

     EFFECTIVE REBATE = TOTAL SLIDES ELIGIBLE FOR REBATE / TOTAL PURCHASES =
     ****************

ACTUAL AGGREGATE VOLUME PURCHASED BY IDEXX AND IDEXX US EQUALS VOLUME PROJECTED
AT THE BEGINNING OF THE YEAR.
<TABLE>
<CAPTION>
          Actual  Purchases  Effective     Calculated   20% Holdback Rebate Paid
          Qtrly.    ($MM)      Rebate      Rebate Each   (millions)  (millions)
           Vol.             %(80MM Vol.) Qtr.(millions)
        (millions)
<S>         <C>     <C>         <C>           <C>           <C>        <C>
1st Qtr     **      ****        ****          ****          ****       ****
2nd Qtr     **      *****       ****          ****          ****       ****
3rd Qtr     **      *****       ****          ****          ****       ****
4th Qtr     **      *****       ****          ****          ****       ****
            --      -----                     ----          ----       ----
            **      *****                     ****          ****       ****
                                True-up:      ****                     ****
                                              ----                     ----
                                  Total:      ****                     ****
                                         ==============              =========
</TABLE>

ACTUAL AGGREGATE VOLUME PURCHASED BY IDEXX AND IDEXX US IS GREATER THAN VOLUME
PROJECTED AT THE BEGINNING OF THE YEAR.
<TABLE>
<CAPTION>
          Actual  Purchases  Effective     Calculated   20% Holdback Rebate Paid
          Qtrly.    ($MM)      Rebate      Rebate Each   (millions)  (millions)
           Vol.             %(80MM Vol.) Qtr.(millions)
        (millions)
<S>         <C>     <C>         <C>           <C>           <C>        <C>
1st Qtr     *       ****        ****          ****          ****       ****
2nd Qtr     **      *****       ****          ****          ****       ****
3rd Qtr     **      *****       ****          ****          ****       ****
4th Qtr     **      *****       ****          ****          ****       ****
            --      -----                     ----          ----       ----
            **      *****                     ****          ****       ****
                                True-up:      ****                     ****
                                              ----                     ----
                                  Total:      ****                     ****
                                         ==============             ==========
</TABLE>
<PAGE> 28
ACTUAL AGGREGATE VOLUME PURCHASED BY IDEXX AND IDEXX US IS LOWER THAN VOLUME
PROJECTED AT THE BEGINNING OF THE YEAR.
<TABLE>
<CAPTION>
          Actual  Purchases  Effective     Calculated   20% Holdback Rebate Paid
          Qtrly.    ($MM)      Rebate      Rebate Each   (millions)  (millions)
           Vol.             %(80MM Vol.)      Qtr.
        (millions)                         (millions)
<S>         <C>     <C>         <C>           <C>           <C>        <C>
1st Qtr     **      ****        ****          ****          ****       ****
2nd Qtr     **      *****       ****          ****          ****       ****
3rd Qtr     **      *****       ****          ****          ****       ****
4th Qtr     **      *****       ****          ****          ****       ****
            --      -----                     ----          ----       ----
            **      *****                     ****          ****       ****
                                True-up:     ******                    ****
                                             ------                    ----
                                  Total:      ****                     ****
                                         ==============             ===========

</TABLE>
CALCULATION OF IDEXX'S PROPORTIONATE SHARE OF REBATE (ASSUMING ACTUAL AGGREGATE
VOLUME PURCHASED BY IDEXX AND IDEXX US EQUALS VOLUME PROJECTED AT THE BEGINNING
OF THE YEAR):

ASSUMPTIONS:
     Number of slides purchased by IDEXX:  ********** slides
     Total number of slides purchase by IDEXX US and its wholly-owned
     subsidiaries:  ********** slides
     Total rebate earned:  ************

CALCULATION:
IDEXX's rebate equals:  *****************************************************

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00017-of-00352.parquet"}]]